Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

NCT01557166 on ClinicalTrials.gov · last registry update 2017-11-01

Finished 1 June 2013, after enrolling 359 people. Primary outcome, as filed: Change From Baseline in Apnoea-hypopnoea Index (AHI). liraglutide is approved in the US, but not for sleep apnea — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 359
Started: 2012-06-07
Primary completion: 2013-06-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Apnoea-hypopnoea Index (AHI)

Conditions studied

Metabolism and Nutrition Disorder · Obesity · Obstructive Sleep Apnoea

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.